Effectiveness and safety of rituximab in severely relapsed antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective analysis of a Japanese multicentre cohort from the J-CANVAS
Genki Kidoguchi,Yusuke Yoshida,Hirofumi Watanabe,Tomohiro Sugimoto,Sho Mokuda,Takashi Kida,Nobuyuki Yajima,Satoshi Omura,Daiki Nakagomi,Yoshiyuki Abe,Masatoshi Kadoya,Naoho Takizawa,Atsushi Nomura,Yuji Kukida,Naoya Kondo,Yasuhiko Yamano,Takuya Yanagida,Koji Endo,Kiyoshi Matsui,Tohru Takeuchi,Kunihiro Ichinose,Masaru Kato,Ryo Yanai,Yusuke Matsuo,Yasuhiro Shimojima,Ryo Nishioka,Ryota Okazaki,Tomoaki Takata,Takafumi Ito,Mayuko Moriyama,Ayuko Takatani,Yoshia Miyawaki,Toshiko Ito-Ihara,Takashi Kawaguchi,Yutaka Kawahito,Shintaro Hirata,Japan Collaborative Registry of ANCA-Associated Vasculitis (J-CANVAS)
DOI: https://doi.org/10.1007/s10067-024-07096-y
2024-08-12
Abstract:We aimed to clarify the long-term safety and efficacy of rituximab (RTX) as a remission induction therapy following severe relapse in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We retrospectively collected the data of patients with severely relapsed AAV from a Japanese multicentre cohort. The primary exposure was RTX use; the primary outcome was complete remission (CR) proportions at week 24. Baseline characteristics were compared between the RTX and non-RTX groups. We performed multivariate logistic regression analysis and one-to-one propensity score matching analysis as a sensitivity analysis. Totally, 100 patients were enrolled: 52 in the RTX group and 48 in the non-RTX group. Baseline characteristics were comparable between the two groups, except for age, AAV subtype and ANCA serotype. The median age was 71 vs. 75 years, and the PR3-ANCA positivity rate was 44.2% vs. 18.8% in the RTX and non-RTX groups, respectively. No significant difference was observed in CR proportions at week 24 between the two groups (79.2% vs. 68.1%, p = 0.321), with an adjusted odds ratio of 1.27 (95% confidence interval [CI] 0.47-3.51). At week 48, CR proportions were significantly higher in the RTX group (91.7% vs. 64.9%, p = 0.005), with an adjusted odds ratio of 2.95 (95% CI 0.97-9.91). Serious infection rates were lower in the RTX group than in the non-RTX group, with no statistically significant difference. RTX was not superior to conventional immunosuppressive therapies at week 24 but showed significantly favourable results at week 48 for severely relapsed AAV.